Table 2.
Significantly enriched GO terms based on genes for which change in expression between IA-1 and IA-2 visits differed (nominal P < 0.01) across the three groups
| Term | Description | N in category | N differentially expressed | Nominal P | FDR Adj. P | Top differentially expressed gene |
|---|---|---|---|---|---|---|
| Biological Process (BP) | ||||||
| GO:0002366 | Leukocyte activation involved in immune response | 389 | 17 | 7.82E−06 | 1.49E−02 | ARSB (P = 7.91E−5) |
| GO:0045055 | Regulated exocytosis | 403 | 17 | 1.19E−05 | 1.55E−02 | PDGFA (P = 9.34E−5) |
| GO:0045087 | Innate immune response | 429 | 17 | 2.75E−05 | 2.44E−02 | RSAD2 (P = 2.02E−3) |
| GO:0002443 | Leukocyte-mediated immunity | 439 | 17 | 4.19E−05 | 2.87E−02 | ARSB (P = 7.91E−5) |
| GO:0002274 | Myeloid leukocyte activation | 354 | 15 | 4.27E−05 | 2.87E−02 | ARSB (P = 7.91E−5) |
| GO:0050776 | Regulation of immune response | 492 | 17 | 1.51E−04 | 8.93E−02 | MAPK9 (P = 1.06E−6) |
| GO:0002697 | Regulation of immune effector process | 236 | 11 | 1.79E−04 | 9.99E−02 | CD86 (P = 1.62E−3) |
| Cellular Component (CC) | ||||||
| GO:0035580 | Specific granule lumen | 46 | 7 | 2.11E−06 | 6.86E−03 | HP (P = 1.54E−3) |
| GO:0005615 | Extracellular space | 1,359 | 34 | 6.06E−05 | 3.94E−02 | PDGFA (P = 9.34E−5) |
The three groups include progressors, reverters, and maintainers. N in category = number of genes within each GO term that were tested in current study (background-adjusted gene set). N differentially expressed = number of genes within each GO term included in differentially expressed gene set (Supplementary Material). Top differentially expressed gene = within each GO term, representing the differentially expressed gene with the smallest P value. The P value was obtained from linear mixed models testing group * visit hypothesis. Adj., adjusted.